Knight Therapeutics Financials
| KHTRF Stock | USD 3.73 0.02 0.53% |
Knight |
Knight Therapeutics Stock Summary
Knight Therapeutics competes with Grey Cloak. Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada. Knight Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 660 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | 3400 De Maisonneuve |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.gud-knight.com |
| Phone | 514 484 4483 |
| Currency | USD - US Dollar |
Knight Therapeutics Key Financial Ratios
There are many critical financial ratios that Knight Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Knight Therapeutics reports annually and quarterly.| Return On Equity | -0.0266 | |||
| Return On Asset | -0.0133 | |||
| Number Of Employees | 660 | |||
| Beta | 0.5 | |||
| Z Score | 28.8 |
Knight Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Knight Therapeutics's current stock value. Our valuation model uses many indicators to compare Knight Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Knight Therapeutics competition to find correlations between indicators driving Knight Therapeutics's intrinsic value. More Info.Knight Therapeutics is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Knight Therapeutics' earnings, one of the primary drivers of an investment's value.Knight Therapeutics Systematic Risk
Knight Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Knight Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Knight Therapeutics correlated with the market. If Beta is less than 0 Knight Therapeutics generally moves in the opposite direction as compared to the market. If Knight Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Knight Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Knight Therapeutics is generally in the same direction as the market. If Beta > 1 Knight Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Knight Therapeutics December 14, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Knight Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Knight Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Knight Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Knight Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Knight Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.26) | |||
| Maximum Drawdown | 10.61 | |||
| Value At Risk | (2.12) | |||
| Potential Upside | 1.6 |
Complementary Tools for Knight Pink Sheet analysis
When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |